NCT03587207View on ClinicalTrials.gov

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

December 19, 2018

Study Completion Date

December 19, 2018

Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL

MenABCWY vaccine

Two doses administered intramuscularly in the deltoid region of the non-dominant arm.

BIOLOGICAL

rMenB+OMV NZ (Bexsero) vaccine

Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group, rMenBOMV+ACWY\_D Group and rMenBOMV Group

BIOLOGICAL

MenACWY (Menveo) vaccine

Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group and rMenBOMV+ACWY\_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group

Trial Locations (1)

50002

GSK Investigational Site, Hradec Králové

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03587207 - Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years | Biotech Hunter | Biotech Hunter